The latest UN estimates show men slightly outnumber women globally, but the future of biopharma is female. As life expectancies increase, women clearly outnumber men at older ages (e.g., 55% of those aged 65 years globally), which means society is facing unprecedented healthcare challenges. Hundreds of millions of women experience diseases that are in need of new therapies and improved access, from treatments for conditions affecting reproductive health to migraines, including social and cultural needs over a lifetime. This translates to a market opportunity, as a recent BCC Research report found these challenges are driving the women’s health market, with an anticipated CAGR of 4.2% through 2023 ($37.4B). Learn how the biopharma industry is uniquely positioned to address these challenges through a global approach.